ReviewMedical sciences (Basel, Switzerland)2026
Interventions for Hypertrophic Obstructive Cardiomyopathy: Defining the Gold Standard, Assessing Durability, and Guiding Patient Selection.
Review in Medical sciences (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hypertrophic obstructive cardiomyopathy (HOCM) is a genetic disorder characterized by a dynamic left ventricular outflow tract (LVOT) obstruction and an increased risk of sudden cardiac death. For patients with symptoms refractory to medical management, or intolerant to the new selective myosin inhibitor, septal reduction therapy (SRT) with surgical septal myectomy (SM) is indicated. This narrative review provides a contemporary assessment of septal myectomy, integrating its historical development, technical advancements, and comparative long-term outcomes. SM is established as the current reference standard, offering extensive anatomical relief and favorable long-term survival in clinical registries. It consistently achieves residual LVOT gradients <10 mmHg and enables correction of complex accessory mitral pathologies, leading to significant reverse ventricular and atrial remodeling. In contrast, ASA, a less invasive alternative for high-risk surgical candidates, is limited by incomplete tissue necrosis. This results in higher residual gradients (15-20 mmHg), increased rates of re-intervention (10-20%) and incidence of permanent pacemaker implantation (10-17.4%) and an associated greater risk of long-term all-cause mortality (>5 years). The disparity in long-term survival and the risk associated with sequential septal reduction procedures underscore the critical need for precise patient selection guided by institutional expertise. Furthermore, advancements like virtual surgical myectomy and transapical beating-heart septal myectomy are expanding the scope of intervention. This review synthesizes comparative contemporary data on HOCM management, highlighting the need for prospective, multicenter studies to address enduring knowledge gaps concerning equitable access, genotype integration, and long-term comparative effectiveness as current evidence remains dominated by retrospective studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.